Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRG-1801 in Relapsed/Refractory Primary Immune Thrombocytopenia (ITP)
NCT06519565Phase 1Recruiting
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of ribrecabtagene autoleucel in immune thrombocytopenia (ITP) (2 arms). Primary endpoints: Incidence of Treatment-related Adverse Events and The safe dosage for a single infusion of PRG-1801. Started Aug 2024; status: recruiting.
02
Drugs
ribrecabtagene autoleucel
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06519565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06519565.